Form 4: Pieris Pharmaceuticals Director Sells Shares
Insider Transaction (Form 4)
George M Jenkins, a Director of Pieris Pharmaceuticals, Inc., sold 27,500 shares of common stock on September 11, 2026.
Summary
- Open-market sale: disposed of 6,520 Common Stock at $150.62 ($982,035) on September 11, 2026; holds 181,096 after (Direct).
- Open-market sale: disposed of 4,577 Common Stock at $151.72 ($694,403) on September 11, 2026; holds 176,519 after (Direct).
- Open-market sale: disposed of 1,274 Common Stock at $153.06 ($194,997) on September 11, 2026; holds 175,245 after (Direct).
- Open-market sale: disposed of 5,632 Common Stock at $151.46 ($853,037) on September 14, 2026; holds 169,613 after (Direct).
- Open-market sale: disposed of 6,160 Common Stock at $152.12 ($937,034) on September 14, 2026; holds 163,453 after (Direct).
- Open-market sale: disposed of 1,560 Common Stock at $153.10 ($238,834) on September 14, 2026; holds 161,893 after (Direct).
- Open-market sale: disposed of 954 Common Stock at $149.38 ($142,507) on September 15, 2026; holds 160,939 after (Direct).
- Open-market sale: disposed of 263 Common Stock at $150.40 ($39,556) on September 15, 2026; holds 160,676 after (Direct).
- Open-market sale: disposed of 560 Common Stock at $151.33 ($84,743) on September 15, 2026; holds 160,116 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,167,146 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
George M Jenkins — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-11 | Open-market sale | Common Stock | 6,520 | $151 | $982.0K | 181,096 |
| 2026-09-11 | Open-market sale | Common Stock | 4,577 | $152 | $694.4K | 176,519 |
| 2026-09-11 | Open-market sale | Common Stock | 1,274 | $153 | $195.0K | 175,245 |
| 2026-09-14 | Open-market sale | Common Stock | 5,632 | $151 | $853.0K | 169,613 |
| 2026-09-14 | Open-market sale | Common Stock | 6,160 | $152 | $937.0K | 163,453 |
| 2026-09-14 | Open-market sale | Common Stock | 1,560 | $153 | $238.8K | 161,893 |
| 2026-09-15 | Open-market sale | Common Stock | 954 | $149 | $142.5K | 160,939 |
| 2026-09-15 | Open-market sale | Common Stock | 263 | $150 | $39.6K | 160,676 |
| 2026-09-15 | Open-market sale | Common Stock | 560 | $151 | $84.7K | 160,116 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-11 | Open-market sale (6,520 shares) |
| 2026-09-11 | Open-market sale (4,577 shares) |
| 2026-09-11 | Open-market sale (1,274 shares) |
| 2026-09-14 | Open-market sale (5,632 shares) |
| 2026-09-14 | Open-market sale (6,160 shares) |
| 2026-09-14 | Open-market sale (1,560 shares) |
| 2026-09-15 | Open-market sale (954 shares) |
| 2026-09-15 | Open-market sale (263 shares) |
| 2026-09-15 | Open-market sale (560 shares) |
Keywords
insider transaction, Form 4, PVLA, PALVELLA THERAPEUTICS, INC., bearish, George M Jenkins
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.